Stay updated with breaking news from Rare Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration.
Glenn J. Hanna, MD, discusses the significance of the FDA approval of toripalimab for patients with recurrent or metastatic nasopharyngeal carcinoma.
Giving the immunotherapy nivolumab to patients with oral proliferative leukoplakia not only reduces lesions but also may prevent cancer progression, suggests the first study in the preventive setting.
- Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck- Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring Principal Investigator Glenn J. Hanna, M.D.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-s...
Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring